The Efficacy of Antibiotic Combination Therapies with Fosfomycin For Multi-Drug Resistant Gram-Negative Bacterial Infections
Abstract
Background: Antimicrobial resistance in Gram-negative bacteria especially infections due to multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan drug-resistant (PDR) strains has narrowed therapeutic options. In the absence of many new agents, older antibiotics are being reconsidered in combination regimens. Fosfomycin, with a unique mechanism and broad spectrum, is a leading candidate in this context.
Objective: To assess whether parenteral fosfomycin-based combinations influence mortality and morbidity in hospitalized adults with MDR/XDR/PDR Gramnegative infections.
Methods: We conducted a retrospective study of adults treated between February 2019 and June 2020 in university hospital ICUs and wards. Patients received either combination therapy including IV fosfomycin (n=141) or combination therapy without fosfomycin (n=137). Demographic, clinical, laboratory and treatment data were extracted from the hospital information system.
Results: Baseline age, sex, APACHE II and SOFA scores were similar between groups, whereas the fosfomycin group had a higher Charlson comorbidity index. No significant difference was observed in 28-day or 60-day mortality between fosfomycin and control groups (p=0.568 and p=0.094, respectively); point estimates favored the fosfomycin group (28-day mortality 41.1% vs 44.5%). Mortality correlated with higher illness severity and invasive device use in both groups. Ten patients receiving fosfomycin developed hypernatremia.
Conclusion: In patients with high illness severity, comorbidity, and invasive device needs, fosfomycin-containing combinations, when used with suitable companion agents and accompanied by careful safety monitoring, constitute a rational treatment option against MDR/XDR/PDR Gram-negative infections. Pharmacokinetic (PK) and pharmacodynamic (PD) data and well-designed clinical studies are required to clarify clinical efficacy and safety.
Keywords
Multidrug resistant, extremely drug resistant, pan drug resistant, fosfomycin
References
- Wei W, Hai-fei Y. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol. Int J Antimicrob Agents. 2017;49(3):321–6.
- Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009;34(2):111–20.
- Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND, et al. Antimicrobial susceptibility of multidrug- resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis. 2008;27(6):439–43.
- Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–47.
- Kowalska-Krochmal, B.; Mączyńska, B.; Rurańska-Smutnicka, D.; Secewicz, A.; Krochmal, G.; Bartelak, M.; Górzyńska, A.; Laufer, K.; Woronowicz, K.; Łubniewska, J.; et al. Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment. Pathogens 2022(11); 1441
- Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents. 2009;34(6):506–15.
- Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol [Internet]. 2010;66(4):359–68.
- Perdigão Neto LV, Oliveira MS, Martins RCR, Marchi AP, Gaudereto JJ, Da Costa LATJ, et al. Fosfomycin in severe infections due to genetically distinct pan-drug-resistant Gram-negative microorganisms: Synergy with meropenem. J Antimicrob Chemother. 2019;74(1):177–81.
- Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: Use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069–77.
- Kobayashi Y, Sumitani Y, Sugita K, Aikawa N. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro. Int J Antimicrob Agents. 2007;30(6):563–4.